vs
Side-by-side financial comparison of Everus Construction Group, Inc. (ECG) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Everus Construction Group, Inc. is the larger business by last-quarter revenue ($1.0B vs $622.0M, roughly 1.6× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 5.5%, a 29.0% gap on every dollar of revenue. On growth, Everus Construction Group, Inc. posted the faster year-over-year revenue change (33.2% vs 4.8%). Over the past eight quarters, Everus Construction Group, Inc.'s revenue compounded faster (27.1% CAGR vs 4.6%).
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
ECG vs RPRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $622.0M |
| Net Profit | $55.3M | $214.2M |
| Gross Margin | 11.6% | — |
| Operating Margin | 6.8% | 62.4% |
| Net Margin | 5.5% | 34.4% |
| Revenue YoY | 33.2% | 4.8% |
| Net Profit YoY | 60.4% | 2.9% |
| EPS (diluted) | $1.09 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $622.0M | ||
| Q3 25 | $986.8M | $609.3M | ||
| Q2 25 | $921.5M | $578.7M | ||
| Q1 25 | $826.6M | $568.2M | ||
| Q4 24 | $759.6M | $593.6M | ||
| Q3 24 | $761.0M | $564.7M | ||
| Q2 24 | $703.4M | $537.3M | ||
| Q1 24 | $625.7M | $568.0M |
| Q4 25 | $55.3M | $214.2M | ||
| Q3 25 | $57.0M | $288.2M | ||
| Q2 25 | $52.8M | $30.2M | ||
| Q1 25 | $36.7M | $238.3M | ||
| Q4 24 | $34.5M | $208.2M | ||
| Q3 24 | $41.8M | $544.0M | ||
| Q2 24 | $39.0M | $102.0M | ||
| Q1 24 | $28.2M | $4.8M |
| Q4 25 | 11.6% | — | ||
| Q3 25 | 12.6% | — | ||
| Q2 25 | 13.0% | — | ||
| Q1 25 | 11.2% | — | ||
| Q4 24 | 11.4% | — | ||
| Q3 24 | 11.8% | — | ||
| Q2 24 | 12.6% | — | ||
| Q1 24 | 11.9% | — |
| Q4 25 | 6.8% | 62.4% | ||
| Q3 25 | 7.3% | 70.1% | ||
| Q2 25 | 7.9% | 36.3% | ||
| Q1 25 | 6.2% | 94.0% | ||
| Q4 24 | 6.1% | 60.9% | ||
| Q3 24 | 7.1% | — | ||
| Q2 24 | 7.3% | 50.2% | ||
| Q1 24 | 6.2% | -13.0% |
| Q4 25 | 5.5% | 34.4% | ||
| Q3 25 | 5.8% | 47.3% | ||
| Q2 25 | 5.7% | 5.2% | ||
| Q1 25 | 4.4% | 41.9% | ||
| Q4 24 | 4.5% | 35.1% | ||
| Q3 24 | 5.5% | 96.3% | ||
| Q2 24 | 5.5% | 19.0% | ||
| Q1 24 | 4.5% | 0.8% |
| Q4 25 | $1.09 | $0.49 | ||
| Q3 25 | $1.11 | $0.67 | ||
| Q2 25 | $1.03 | $0.07 | ||
| Q1 25 | $0.72 | $0.55 | ||
| Q4 24 | $0.68 | $0.46 | ||
| Q3 24 | $0.82 | $1.21 | ||
| Q2 24 | $0.76 | $0.23 | ||
| Q1 24 | $0.55 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $618.7M |
| Total DebtLower is stronger | $281.5M | $9.0B |
| Stockholders' EquityBook value | $629.8M | $9.7B |
| Total Assets | $1.7B | $19.6B |
| Debt / EquityLower = less leverage | 0.45× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | — | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $929.0M | ||
| Q3 24 | $553.0K | $950.1M | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $843.0M |
| Q4 25 | $281.5M | $9.0B | ||
| Q3 25 | $285.1M | $8.9B | ||
| Q2 25 | $288.6M | $8.0B | ||
| Q1 25 | $292.1M | $7.6B | ||
| Q4 24 | $295.6M | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
| Q4 25 | $629.8M | $9.7B | ||
| Q3 25 | $573.0M | $9.6B | ||
| Q2 25 | $514.4M | $9.5B | ||
| Q1 25 | $460.2M | $9.8B | ||
| Q4 24 | $422.6M | $10.3B | ||
| Q3 24 | $453.3M | $10.3B | ||
| Q2 24 | $490.0M | $9.8B | ||
| Q1 24 | $464.3M | $9.9B |
| Q4 25 | $1.7B | $19.6B | ||
| Q3 25 | $1.6B | $19.3B | ||
| Q2 25 | $1.5B | $18.3B | ||
| Q1 25 | $1.4B | $17.6B | ||
| Q4 24 | $1.3B | $18.2B | ||
| Q3 24 | $1.3B | $18.0B | ||
| Q2 24 | — | $17.7B | ||
| Q1 24 | — | $16.1B |
| Q4 25 | 0.45× | 0.92× | ||
| Q3 25 | 0.50× | 0.93× | ||
| Q2 25 | 0.56× | 0.84× | ||
| Q1 25 | 0.63× | 0.78× | ||
| Q4 24 | 0.70× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $48.2M | $827.1M |
| Free Cash FlowOCF − Capex | $23.5M | — |
| FCF MarginFCF / Revenue | 2.3% | — |
| Capex IntensityCapex / Revenue | 2.4% | — |
| Cash ConversionOCF / Net Profit | 0.87× | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | $90.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $48.2M | $827.1M | ||
| Q3 25 | $76.2M | $702.6M | ||
| Q2 25 | $25.3M | $364.0M | ||
| Q1 25 | $7.1M | $596.1M | ||
| Q4 24 | — | $742.5M | ||
| Q3 24 | $78.9M | $703.6M | ||
| Q2 24 | — | $658.2M | ||
| Q1 24 | $21.9M | $664.6M |
| Q4 25 | $23.5M | — | ||
| Q3 25 | $65.7M | — | ||
| Q2 25 | $12.3M | — | ||
| Q1 25 | $-11.4M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $60.9M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $12.6M | — |
| Q4 25 | 2.3% | — | ||
| Q3 25 | 6.7% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | -1.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.0% | — |
| Q4 25 | 2.4% | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 1.4% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.5% | — |
| Q4 25 | 0.87× | 3.86× | ||
| Q3 25 | 1.34× | 2.44× | ||
| Q2 25 | 0.48× | 12.06× | ||
| Q1 25 | 0.19× | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | 1.89× | 1.29× | ||
| Q2 24 | — | 6.45× | ||
| Q1 24 | 0.77× | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ECG
| Commercial | $594.5M | 59% |
| Utility | $203.5M | 20% |
| Industrial | $82.8M | 8% |
| Institutional | $66.1M | 7% |
| Service And Other | $28.4M | 3% |
| Transportation | $24.2M | 2% |
| Renewables | $19.8M | 2% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
